Nabothian Cyst Protects or Facilitates Against Cervical Cancer

NCT04488991UNKNOWNOBSERVATIONAL

Summary

Key Facts

Lead Sponsor

Haseki Training and Research Hospital

Enrollment

1005

Start Date

2020-07-23

Completion Date

2021-03-01

Study Type

OBSERVATIONAL

Official Title

Naboth Kisti ve HPV pozitifliği arasındaki ilişkinin araştırılması

Interventions

Cervical Cancer Rate

Conditions

HPV InfectionNabothian CystCervical Cancer

Eligibility

Age Range

25 Years – 65 Years

Sex

FEMALE

Inclusion Criteria:

To have Naboth cyst and/or HPV positivity Must be willing and able to provide informed consent Comply with the study protocol Between 25-65 age range

Exclusion Criteria:

To Refuse participate in our research The age under 25 and over 65 Ovarian, endometrial and vulvar malignancies Without both Naboth's cyst and HPV positivity To have LEEP/Cervical Conization before History of Cervical Dysplasia

Outcome Measures

Primary Outcomes

Nabothian cyst affects the HPV infection in cervix

in the research, results will be compared for to figure out the relation; nabothian cyst how affects HPV infection , how causes cervical dysplasia in cervix.

Time frame: through study completion, an average of 1 year

Secondary Outcomes

Does the other factors(like cigarette, birth number, vaginitis) affect HPV infection and Cervical Cancer

In the research Other factors(like cigarette, birth number, vaginitis) will be also noted. These datas will be used to understand correlation; the other factors increase or decreate the rate of HPV infection and cervical dysplasia.

Time frame: through study completion, an average of 1 year

Locations

Cihan Comba, Istanbul, Turkey (Türkiye)

Linked Papers

2020-05-26

Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta‐analysis

AbstractMost women positive for human papillomavirus (HPV) are cytology normal. The optimal screen‐management of these women is unclear given their risk of developing precancer. We performed a systematic review and meta‐analysis of progression rates to precancer and cancer for HPV‐positive, cytology normal women. We searched MEDLINE, EMBASE and Scopus for prospective studies measuring the cumulative incidence of precancer and cervical cancer in HPV‐positive, cytology/histology normal women. Record screening was performed independently by two reviewers. We modeled the cumulative incidence over time using a multilevel random‐effects meta‐regression model. We used the model to predict HPV type‐specific risks of precancer and cancer over follow‐up. Data from 162 unique records were used in our analysis. The average incidence rate of cervical intraepithelial neoplasia grade 3 or cancer (CIN3+) in high‐risk HPV positive but cytology/histology normal women was 1.0 per 100 women‐years (95% CI: 1.0‐1.1). This corresponds to an average cumulative risk at 1, 3 and 5 years of 2.1% (95% prediction interval 0.0‐9.5), 4.3% (95% prediction interval 0.0‐11.5) and 6.4% (95% prediction interval 0.0‐13.5). HPV type was a strong predictor of the risk of oncogenic progression. There was substantial heterogeneity in the background precancer risk across studies (P‐value < .0001). Our HPV type‐specific progression risk estimates can help inform risk‐based cervical cancer screening guidelines for HPV‐positive women. However, precancer and cervical cancer risks are highly variable and may not be generalizable between populations.

Linked Investigators

Eduardo L. Franco

Professor Eduardo Franco is a Distinguished James McGill Professor in the Departments of Oncology and Epidemiology & Biostatistics at McGill University. He served as Director of the Division of Cancer Epidemiology (1995–2024) and Chair of the Department of Oncology (2011–23). Earlier, he was on the faculty of Université du Québec and Head of the Epidemiology Unit at the Ludwig Institute for Cancer Research in São Paulo, Brazil. He holds biology degrees from the Universidade de Campinas and MPH and DrPH degrees from the University of North Carolina at Chapel Hill. His early training included fellowships at the U.S. Centers for Disease Control, the International Agency for Research on Cancer, the U.S. National Cancer Institute, and Louisiana State University. Since 1985, his research has contributed to understanding and preventing cervical cancer and HPV‑related diseases, and to studies of upper aerodigestive tract, prostate, endometrial, and childhood cancers. His work spans cancer screening evaluation, measurement error, and factors influencing cancer survival. He has led international collaborations in the Americas, Europe, Africa, and through IARC. His research has been funded by CIHR, NIH, the National Cancer Institute of Canada, the Canadian Cancer Society, FRSQ, and the Cancer Research Society. As of March 2026, he had published more than 600 scientific papers (Google Scholar link: https://scholar.google.com/citations?user=9GDejd4AAAAJ&hl=en). His work has appeared in The Lancet, JAMA, NEJM, JNCI, BMJ, and PLOS Medicine. He is Editor‑in‑Chief of the Journal of the National Cancer Institute and JNCI Monographs, and Editor‑in‑Chief Emeritus of Preventive Medicine and Preventive Medicine Reports. He has served on more than a dozen major editorial boards, on scientific and grant‑review panels internationally, and twice advised the U.S. President’s Cancer Panel. Professor Franco has mentored 101 graduate students, 36 postdoctoral fellows, and 41 undergraduate trainees, and has taught widely in North America, Latin America, Europe, Asia, and the Middle East. He has held leadership roles in 68 conference committees, chaired the 16th World Congress of Epidemiology, and served as Vice-President and President of the Canadian Society for Epidemiology and Biostatistics. He is President‑Elect of the International Epidemiological Association (2024–27). His honours include major lifetime achievement awards from McGill and international organizations, and national distinctions such as Officer of the Order of Canada, Fellow of the Royal Society of Canada, the Canadian Academy of Health Sciences, and Foreign Fellow of the Brazilian Academy of Sciences.